JP2016533753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533753A5 JP2016533753A5 JP2016537898A JP2016537898A JP2016533753A5 JP 2016533753 A5 JP2016533753 A5 JP 2016533753A5 JP 2016537898 A JP2016537898 A JP 2016537898A JP 2016537898 A JP2016537898 A JP 2016537898A JP 2016533753 A5 JP2016533753 A5 JP 2016533753A5
- Authority
- JP
- Japan
- Prior art keywords
- kynureninase
- present
- therapy
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872132P | 2013-08-30 | 2013-08-30 | |
| US61/872,132 | 2013-08-30 | ||
| US201461986366P | 2014-04-30 | 2014-04-30 | |
| US61/986,366 | 2014-04-30 | ||
| PCT/US2014/053437 WO2015031771A2 (en) | 2013-08-30 | 2014-08-29 | Administration of kynurenine depleting enzymes for tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018042760A Division JP7029316B2 (ja) | 2013-08-30 | 2018-03-09 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533753A JP2016533753A (ja) | 2016-11-04 |
| JP2016533753A5 true JP2016533753A5 (enExample) | 2017-10-05 |
| JP6307163B2 JP6307163B2 (ja) | 2018-04-04 |
Family
ID=52583559
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537898A Active JP6307163B2 (ja) | 2013-08-30 | 2014-08-29 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2018042760A Active JP7029316B2 (ja) | 2013-08-30 | 2018-03-09 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2020073212A Withdrawn JP2020111611A (ja) | 2013-08-30 | 2020-04-16 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2022132161A Pending JP2022159570A (ja) | 2013-08-30 | 2022-08-23 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018042760A Active JP7029316B2 (ja) | 2013-08-30 | 2018-03-09 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2020073212A Withdrawn JP2020111611A (ja) | 2013-08-30 | 2020-04-16 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2022132161A Pending JP2022159570A (ja) | 2013-08-30 | 2022-08-23 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9808486B2 (enExample) |
| EP (2) | EP3492094A1 (enExample) |
| JP (4) | JP6307163B2 (enExample) |
| KR (2) | KR102271498B1 (enExample) |
| CN (2) | CN113957061A (enExample) |
| AU (1) | AU2014312119B2 (enExample) |
| BR (1) | BR112016004095A2 (enExample) |
| CA (2) | CA3173052A1 (enExample) |
| ES (1) | ES2707711T3 (enExample) |
| IL (2) | IL244312B (enExample) |
| WO (1) | WO2015031771A2 (enExample) |
| ZA (1) | ZA201601443B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR102271498B1 (ko) | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| EP3186371B1 (en) * | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| JP2018510652A (ja) * | 2015-03-18 | 2018-04-19 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体 |
| EP3402498A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| EP3423483B1 (en) * | 2016-03-02 | 2025-09-24 | Board Of Regents Of the University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| JP7623784B2 (ja) | 2016-10-13 | 2025-01-29 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| JP2020527025A (ja) * | 2017-07-12 | 2020-09-03 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| WO2019089740A1 (en) * | 2017-11-03 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| BR112020020772A2 (pt) | 2018-04-16 | 2021-02-02 | Board Of Regents, The University Of Texas System | enzimas quinureninase humana e usos das mesmas |
| CN110412179A (zh) * | 2018-04-26 | 2019-11-05 | 缪荣明 | 一种液相色谱检测颗粒酶a的方法 |
| EP3893923A2 (en) * | 2018-12-14 | 2021-10-20 | Autolus Limited | Cell |
| CN114828863A (zh) * | 2019-10-17 | 2022-07-29 | 医肯纳肿瘤学公司 | 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途 |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| WO2023229024A1 (ja) * | 2022-05-27 | 2023-11-30 | 富士フイルム株式会社 | 血液腫瘍の診断を補助する方法、血液腫瘍の診断を行うためのデータを得る方法、及びこれらの方法のためのキット |
| WO2024085280A1 (ko) * | 2022-10-20 | 2024-04-25 | 서울대학교 산학협력단 | 신규한 키뉴레니나제 및 이의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20030194721A1 (en) | 2001-09-19 | 2003-10-16 | Incyte Genomics, Inc. | Genes expressed in treated foam cells |
| JP2005516605A (ja) | 2002-02-01 | 2005-06-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 心血管疾患を処置するための方法および組成物 |
| CN1330774C (zh) * | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0625310D0 (en) * | 2006-12-19 | 2007-01-24 | Bioalvo | Yeast platform construction and screening methods |
| CA2776143A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| ES2602743T3 (es) | 2010-09-08 | 2017-02-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20120085209A (ko) * | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| US9593062B2 (en) * | 2011-09-07 | 2017-03-14 | Deutschland Krebsforschungszentrum | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| KR102271498B1 (ko) * | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| EP3186371B1 (en) | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3423483B1 (en) | 2016-03-02 | 2025-09-24 | Board Of Regents Of the University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP6912171B2 (ja) * | 2016-09-15 | 2021-07-28 | 株式会社トプコン | 眼科検査装置 |
| BR112020020772A2 (pt) | 2018-04-16 | 2021-02-02 | Board Of Regents, The University Of Texas System | enzimas quinureninase humana e usos das mesmas |
-
2014
- 2014-08-29 KR KR1020167008486A patent/KR102271498B1/ko active Active
- 2014-08-29 BR BR112016004095A patent/BR112016004095A2/pt not_active Application Discontinuation
- 2014-08-29 US US14/473,040 patent/US9808486B2/en active Active
- 2014-08-29 AU AU2014312119A patent/AU2014312119B2/en active Active
- 2014-08-29 EP EP18204264.8A patent/EP3492094A1/en not_active Withdrawn
- 2014-08-29 ES ES14840339T patent/ES2707711T3/es active Active
- 2014-08-29 CN CN202111132607.1A patent/CN113957061A/zh active Pending
- 2014-08-29 CN CN201480053899.1A patent/CN105722522B/zh active Active
- 2014-08-29 JP JP2016537898A patent/JP6307163B2/ja active Active
- 2014-08-29 CA CA3173052A patent/CA3173052A1/en active Pending
- 2014-08-29 WO PCT/US2014/053437 patent/WO2015031771A2/en not_active Ceased
- 2014-08-29 KR KR1020217019661A patent/KR102442231B1/ko active Active
- 2014-08-29 CA CA2922670A patent/CA2922670C/en active Active
- 2014-08-29 EP EP14840339.7A patent/EP3038636B1/en active Active
-
2016
- 2016-02-28 IL IL244312A patent/IL244312B/en active IP Right Grant
- 2016-03-02 ZA ZA2016/01443A patent/ZA201601443B/en unknown
- 2016-11-14 US US15/351,060 patent/US20170056449A1/en not_active Abandoned
-
2018
- 2018-03-09 JP JP2018042760A patent/JP7029316B2/ja active Active
-
2019
- 2019-02-19 IL IL264901A patent/IL264901B/en active IP Right Grant
- 2019-04-02 US US16/373,588 patent/US10772913B2/en active Active
-
2020
- 2020-04-16 JP JP2020073212A patent/JP2020111611A/ja not_active Withdrawn
- 2020-08-18 US US16/996,806 patent/US11534463B2/en active Active
-
2022
- 2022-08-23 JP JP2022132161A patent/JP2022159570A/ja active Pending
- 2022-12-13 US US18/065,451 patent/US20240091258A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533753A5 (enExample) | ||
| TWI669311B (zh) | Ｉｌ－１５異源二聚體蛋白及其用途 | |
| Gildener-Leapman et al. | Promising systemic immunotherapies in head and neck squamous cell carcinoma | |
| JP6731405B2 (ja) | ウイルス粒子を用いた癌免疫療法 | |
| CN116723851A (zh) | 白介素-18变体和使用方法 | |
| CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
| JP2018505893A5 (enExample) | ||
| JP2019507582A5 (enExample) | ||
| US8597647B1 (en) | Humanized anti-IL-20 antibody and uses thereof | |
| WO2008109155A2 (en) | Compositions and methods for treatment of cervical cancer | |
| JP7099956B2 (ja) | がんの治療のためのｍｉｃａ／ｂアルファ３ドメインによるワクチン接種 | |
| JP2017526368A5 (enExample) | ||
| JP2021521777A5 (enExample) | ||
| CN112955168A (zh) | 与另一种药理活性剂组合的长效白介素-15受体激动剂 | |
| JP2021521777A (ja) | ヒトキヌレニナーゼ酵素及びその使用 | |
| Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
| EP4471068A1 (en) | Bifunctional molecule formed by fusion of pd1 antibody and interleukin 2 | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| JP2021506320A5 (enExample) | ||
| US20230406927A1 (en) | Masked single-domain antibodies and methods thereof | |
| CN101210048A (zh) | 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途 | |
| US20240115675A1 (en) | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine | |
| WO2021260685A1 (en) | Modified cxcl10 for immunotherapy of cancer diseases | |
| WO2008037225A1 (es) | Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico | |
| KR102666000B1 (ko) | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |